Background

A global healthcare research and endpoint technology company offering comprehensive evidence generation solutions that combine eCOA, cardiac safety, medical imaging, and respiratory endpoints sought to future-proof its growth strategy amid rapid shifts in clinical trial technology and sponsor expectations. Despite a dominant position in Cardiac Safety and Respiratory endpoints, the company faced rising pressure to differentiate beyond operational scale—toward innovation in digital endpoints, AI-enabled analytics, and decentralized trial enablement. The objective was to define a forward-looking commercial and innovation strategy that sustains leadership while expanding into adjacent growth territories.

Our approach

In eight weeks, Larka conducted a pragmatic, data-driven strategy engagement combining market intelligence, customer insight, and internal capability analysis to help the client future-proof its leadership in endpoint technologies. The work focused on three core pillars: (i) Market and Competitive Mapping – assessed the current and projected demand for endpoint solutions across therapeutic areas and sponsor types using public clinical trial datasets, published benchmarks, and proprietary market intelligence. Benchmarked the client’s scale and offering against full-service CROs, technology providers, and emerging digital health entrants. (ii) Customer Voice and Adoption Trends – conducted 50+ structured interviews with clinical operations leaders at pharma and biotech sponsors to understand endpoint selection drivers, perceptions of quality, and emerging adoption patterns for digital and hybrid endpoints and (iii) Strategic Growth Roadmap – synthesized quantitative and qualitative findings to define realistic growth priorities and partnership opportunities.

Outcome

The engagement provided a clear view of the company’s market position and growth priorities. It confirmed leadership in Cardiac Safety and Respiratory, identified targeted opportunities in Imaging and eCOA, and outlined a focused roadmap for expansion into digital and AI-enabled endpoints. The findings refined commercial messaging and guided investment decisions to strengthen differentiation and accelerate growth across key sponsor segments.